JP2001517631A - 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤 - Google Patents

炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤

Info

Publication number
JP2001517631A
JP2001517631A JP2000512552A JP2000512552A JP2001517631A JP 2001517631 A JP2001517631 A JP 2001517631A JP 2000512552 A JP2000512552 A JP 2000512552A JP 2000512552 A JP2000512552 A JP 2000512552A JP 2001517631 A JP2001517631 A JP 2001517631A
Authority
JP
Japan
Prior art keywords
lactacystin
proteasome
lactone
agent
ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000512552A
Other languages
English (en)
Japanese (ja)
Inventor
ピーター・エリオット
ジュリアン・アダムズ
ルイス・プラモンドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2001517631A publication Critical patent/JP2001517631A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
JP2000512552A 1997-09-25 1998-09-25 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤 Pending JP2001517631A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6103897P 1997-09-25 1997-09-25
US60/061,038 1997-09-25
US6956297P 1997-12-12 1997-12-12
US60/069,562 1997-12-12
US7488798P 1998-02-17 1998-02-17
US60/074,887 1998-02-17
PCT/US1998/020065 WO1999015183A1 (fr) 1997-09-25 1998-09-25 INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-λB PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES

Publications (1)

Publication Number Publication Date
JP2001517631A true JP2001517631A (ja) 2001-10-09

Family

ID=27369960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000512552A Pending JP2001517631A (ja) 1997-09-25 1998-09-25 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤

Country Status (5)

Country Link
EP (1) EP1017398A1 (fr)
JP (1) JP2001517631A (fr)
AU (1) AU9580098A (fr)
CA (1) CA2304622A1 (fr)
WO (1) WO1999015183A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425632A1 (fr) 2000-10-12 2002-04-18 Viromics Gmbh Moyens pour le traitement d'infections a des virus
DE10051716A1 (de) * 2000-10-12 2002-04-25 Ulrich Schubert Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren
US7144723B2 (en) 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
EP1355910B1 (fr) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation de composes d'acide boronique
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
CA2447909C (fr) 2001-05-21 2011-04-05 Alcon, Inc. Utilisation d'inhibiteurs de proteasome pour traiter des secheresses de l'oeil
AU2002360453C1 (en) * 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
DE10316735A1 (de) 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8217072B2 (en) 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
DE602004031614D1 (de) 2003-06-20 2011-04-14 Nereus Pharmaceuticals Inc Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) * 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
EP1637529A1 (fr) 2004-09-20 2006-03-22 4Sc Ag Nouveaux analogues de piperidin-4-yl-thiazole-carboxamide en tant qu'inhibiteurs de proliferation de lymphocytes T er leurs utilisations
KR101282191B1 (ko) 2004-12-03 2013-07-08 다나-파버 캔서 인스티튜트 인크. 신생물성 질환을 치료하는 조성물 및 방법
CN101460457B (zh) 2006-04-06 2012-07-18 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
WO2008095195A2 (fr) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Formulations lyophilisées de salinosporamide a
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
JP2011514352A (ja) 2008-03-07 2011-05-06 ネレアス ファーマシューティカルズ インコーポレイテッド サリノスポラミドａおよびその類似体の全合成
AU2009246467A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
GEP201706703B (en) 2008-06-17 2017-07-25 Millennium Pharmaceuticals Inc (A Delaware Corporation) Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
DE102010039631A1 (de) * 2010-08-22 2012-02-23 Ulrich Schubert Pharmazeutische Zusammensetzungen mit immunmodulatorischen Eigenschaften
IN2013MU01431A (fr) 2013-04-16 2015-06-26 Cipla Ltd
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs

Also Published As

Publication number Publication date
AU9580098A (en) 1999-04-12
EP1017398A1 (fr) 2000-07-12
WO1999015183A1 (fr) 1999-04-01
CA2304622A1 (fr) 1999-04-01
WO1999015183A9 (fr) 1999-07-29

Similar Documents

Publication Publication Date Title
JP2001517631A (ja) 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US5525623A (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
US20060241130A1 (en) Anti-inflammatory compositions and uses thereof
RU2144027C1 (ru) Изохинолины, способ их получения и фармацевтическая композиция на их основе
US20010051654A1 (en) Treatment of inflammatory and autoimmune diseases
US6576766B1 (en) Signal transduction inhibitors, compositions containing them
JP2011500602A (ja) Ｎ−アシルエタノールアミン−加水分解酸性アミダーゼを阻害する組成物及び方法
US9539221B2 (en) Method of treating airway diseases with β-adrenergic inverse agonists
US20070088003A1 (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU683459B2 (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
EP2164507B1 (fr) Traitement d'une maladie allergique avec des composés immunomodulateurs
EP1931656B1 (fr) Nouveaux medicaments contre la demence
CA2192984A1 (fr) Composes au lactame inhibiteurs de la cholesterol-esterase
Israel-Biet et al. Drug-induced lung disease: 1990 review
CA2337898A1 (fr) Agents pour traiter les affections allergiques
JP2746832B2 (ja) 眼局所抗アレルギー剤
EP1101492A1 (fr) Medicaments contre les maladies allergiques
MXPA00002938A (en) PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-&kgr;B VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
EP1192944B1 (fr) Utilisation de pregabaline dans le traitement de l'asthme
JPS63156789A (ja) トリアゾロ〔１，５−ｃ〕ピリミジンの代謝産物
EP3858357A1 (fr) Utilisation de composés d'azole pour stimuler le système immunitaire et d'inhibiteurs des s-pla2gib
Wolanin et al. Pulmonary and Anti-Allergy Agents
WO2004112791A1 (fr) Agent therapeutique et/ou prophylactique pour maladie pulmonaire
MXPA01000563A (en) Novel remedies for allergic diseases
JPWO2004087147A1 (ja) 肺疾患の治療および／または予防剤